Catumaxomab (Removab) for the indication ‘malignant ascites’

The most important effect of catumaxomab in clinical research is a statistically significant 35-day extension in ‘puncture-free survival’, however without any statistically significant effects on general survival in the entire study population or in the prospectively specified subgroups.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.